ClinicalTrials.gg
CompletedNCT03441568Updated Jul 24, 2020

In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control

An interventional study of Modified Diprobase formulation (BAY987534) in Atopic Dermatitis, sponsored by Bayer. Completed at 1 site in United Kingdom. Open to participants aged 6 Months to 48 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-24.

Sponsored by Bayer · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
6 Months to 48 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Dermatitis, Atopic by Bayer — none open to participants now, none under way, none of them phase 3. Dermatitis, Atopic · Bayer.

Enrollment
8th of 13
40 · median 42
Started
2018
with 1 other
No phase
5 of 14
none open now
Registered
11th of 14
by date

Among the 14 studies in Dermatitis, Atopic by Bayer, this one is the 8th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2018, is one of 5 with no phase, and was the 11th registered.

Dermatitis, Atopic

1,595 studies on the registry are indexed under Dermatitis, Atopic; 288 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

None of the 14 studies in Dermatitis, Atopic by Bayer is open now. The open studies under Dermatitis, Atopic, anywhere →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 6 Months to 48 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Dermatitis, Atopic by Bayer as a file.
02

Study summary

To investigate the safety and tolerability of the modified Diprobase formulation over 14 days in infants and children with a history of Atopic Dermatitis (AD).

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
6 Months to 48 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

  • Children with normal or dry skin and a history of mild to moderate AD, but without any signs or symptoms within the last month prior to enrollment
  • Skin type I - VI according to Fitzpatrick skin classification
  • Aged 6 months to 48 months
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    BAY987534

    Infants and children with quiescent atopic dermatitis

    Device: Modified Diprobase formulation (BAY987534)

Interventions

  • DeviceModified Diprobase formulation (BAY987534)

    The modified Diprobase formulation will be applied topically twice daily over 14 days on the whole body and face.

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse event (AE)

    Time frame: Up to 14 days

  2. Severity of adverse event

    The intensity of an AE is classified according to the following categories: * Mild * Moderate * Severe

    Time frame: Up to 14 days

07

Study locations

1 site
  • West Timperley Medical Centre
    Altrincham, WA14 5PF, United Kingdom
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2018 to primary completion in Aug 2019, 10 months.

Of 69 industry-sponsored interventional studies with no phase under Dermatitis, Atopic, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 24. This study's 10 months is above that.

Counting every sponsor, half of 183 studies reached it within 15 months; a quarter within 7 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2018
First posted
Feb 22, 2018
StartActual
Sep 26, 2018
Primary completionActual
Aug 2, 2019
CompletionActual
Aug 2, 2019
Last update
Jul 24, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03441568
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Feb 22, 2018
Start date
Sep 26, 2018
Primary completion
Aug 2, 2019
Completion
Aug 2, 2019
Last update
Jul 24, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion